T S G Sehested1, T A Gerds1,2, E L Fosbøl3, P W Hansen1,4, M G Charlot5, N Carlson1,6, M A Hlatky4, C Torp-Pedersen7, G H Gislason1,3,8. 1. Department of Cardiovascular Epidemiology and Research, The Danish Heart Foundation, Copenhagen K, Denmark. 2. Department of Biostatistics, Copenhagen University, Copenhagen, Denmark. 3. The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Denmark. 4. Department of Health Research and Policy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. 5. Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte, Denmark. 6. Department of Internal Medicine, Gastroenterology section, Holbaek Hospital, Holbaek, Denmark. 7. Department of Health, Science and Technology, Department of Cardiology and Epidemiology/Biostatistics, Aalborg University, Aalborg University Hospital, Hellerup, Denmark. 8. The National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.
Abstract
BACKGROUND: Use of proton pump inhibitors (PPIs) has been associated with cardiovascular disease amongst patients not on antiplatelet therapy. The associations of PPI use, duration and dose, with risk of first-time ischemic stroke and myocardial infarction (MI) are poorly understood. METHODS: All Danish individuals with no prior history of MI or stroke, who had an elective upper gastrointestinal endoscopy performed between 1997 and 2012, were identified from nationwide registries. We used multiple Poisson regression to test associations with current PPI use and its dose and used multiple cause-specific Cox regression and g-formula methods to analyze long-term use. RESULTS: Amongst 214 998 individuals, during a median follow-up of 5.8 years, there were 7916 ischemic strokes and 5608 MIs. Current PPI exposure was associated with significantly higher rates of both ischemic stroke (Hazard ratio (HR) 1.13; 95% confidence interval (CI) 1.08-1.19) and MI (HR 1.31, CI 1.23-1.39) after adjusting for age, sex, comorbidities and concomitant medication. High-dose PPI was associated with increased rates of ischemic stroke (HR 1.31, CI 1.21-1.42) and MI (HR 1.43, CI 1.30-1.57). Histamine H2 receptor antagonists (H2RAs) use was not significantly associated with ischemic stroke (HR 1.02, CI 0.84-1.24) or MI (HR 1.15, CI 0.92-1.43). Long-term users of PPIs, compared with nonusers, had a 29% (CI 5%-59%) greater absolute risk of ischemic stroke and a 36% (CI 7%-73%) greater risk of MI within a 6-month period. CONCLUSION: Use of PPIs was associated with increased risks of first-time ischemic stroke and MI, particularly amongst long-term users and at high doses.
BACKGROUND: Use of proton pump inhibitors (PPIs) has been associated with cardiovascular disease amongst patients not on antiplatelet therapy. The associations of PPI use, duration and dose, with risk of first-time ischemic stroke and myocardial infarction (MI) are poorly understood. METHODS: All Danish individuals with no prior history of MI or stroke, who had an elective upper gastrointestinal endoscopy performed between 1997 and 2012, were identified from nationwide registries. We used multiple Poisson regression to test associations with current PPI use and its dose and used multiple cause-specific Cox regression and g-formula methods to analyze long-term use. RESULTS: Amongst 214 998 individuals, during a median follow-up of 5.8 years, there were 7916 ischemic strokes and 5608 MIs. Current PPI exposure was associated with significantly higher rates of both ischemic stroke (Hazard ratio (HR) 1.13; 95% confidence interval (CI) 1.08-1.19) and MI (HR 1.31, CI 1.23-1.39) after adjusting for age, sex, comorbidities and concomitant medication. High-dose PPI was associated with increased rates of ischemic stroke (HR 1.31, CI 1.21-1.42) and MI (HR 1.43, CI 1.30-1.57). Histamine H2 receptor antagonists (H2RAs) use was not significantly associated with ischemic stroke (HR 1.02, CI 0.84-1.24) or MI (HR 1.15, CI 0.92-1.43). Long-term users of PPIs, compared with nonusers, had a 29% (CI 5%-59%) greater absolute risk of ischemic stroke and a 36% (CI 7%-73%) greater risk of MI within a 6-month period. CONCLUSION: Use of PPIs was associated with increased risks of first-time ischemic stroke and MI, particularly amongst long-term users and at high doses.
Authors: Long H Nguyen; Paul Lochhead; Amit D Joshi; Yin Cao; Wenjie Ma; Hamed Khalili; Eric B Rimm; Kathryn M Rexrode; Andrew T Chan Journal: Gastroenterology Date: 2017-12-19 Impact factor: 22.682
Authors: Søren Marker; Anders Perner; Jørn Wetterslev; Mette Krag; Theis Lange; Matt P Wise; Mark Borthwick; Stepani Bendel; Frederik Keus; Anne Berit Guttormsen; Joerg C Schefold; Morten Hylander Møller Journal: Intensive Care Med Date: 2019-03-12 Impact factor: 17.440
Authors: Elizabeth J Bell; Suzette J Bielinski; Jennifer L St Sauver; Lin Y Chen; Mary R Rooney; Nicholas B Larson; Paul Y Takahashi; Aaron R Folsom Journal: Mayo Clin Proc Date: 2021-10 Impact factor: 11.104
Authors: Mary R Rooney; Elizabeth J Bell; Alvaro Alonso; James S Pankow; Ryan T Demmer; Kyle D Rudser; Lin Y Chen; Pamela L Lutsey Journal: J Clin Gastroenterol Date: 2021-09-01 Impact factor: 3.174